Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilaprisan versus ulipristal for uterine fibroids
NL-OMON48550Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of vilaprisan in Fibromyoma (LM) (4 arms), sponsored by Bayer. Primary endpoints: Primary efficacy objective and Primary safety objective. Started Nov 2018; status: active, not recruiting.
02
Drugs
vilaprisan
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on NL-OMON48550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48550.